These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15227623)

  • 1. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community.
    Springer SA; Pesanti E; Hodges J; Macura T; Doros G; Altice FL
    Clin Infect Dis; 2004 Jun; 38(12):1754-60. PubMed ID: 15227623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.
    Meyer JP; Cepeda J; Wu J; Trestman RL; Altice FL; Springer SA
    JAMA Intern Med; 2014 May; 174(5):721-9. PubMed ID: 24687044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment regimen outcomes among HIV-infected prisoners.
    Springer SA; Friedland GH; Doros G; Pesanti E; Altice FL
    HIV Clin Trials; 2007; 8(4):205-12. PubMed ID: 17720660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of reincarceration and disease progression among released HIV-infected inmates.
    Baillargeon J; Giordano TP; Harzke AJ; Spaulding AC; Wu ZH; Grady JJ; Baillargeon G; Paar DP
    AIDS Patient Care STDS; 2010 Jun; 24(6):389-94. PubMed ID: 20565323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals.
    Stephenson BL; Wohl DA; Golin CE; Tien HC; Stewart P; Kaplan AH
    Public Health Rep; 2005; 120(1):84-8. PubMed ID: 15736336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.
    Meyer JP; Cepeda J; Springer SA; Wu J; Trestman RL; Altice FL
    Lancet HIV; 2014 Nov; 1(2):e77-e84. PubMed ID: 25473651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
    Resino S; M Bellón J; Gurbindo D; Tomás Ramos J; Antonio León J; Jose Mellado M; Angeles Muñoz-Fernández M
    Clin Infect Dis; 2003 Nov; 37(9):1216-25. PubMed ID: 14557967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An audit of HIV care in English prisons.
    Chan SY; Marsh K; Lau R; Pakianathan M; Hughes G
    Int J STD AIDS; 2015 Jun; 26(7):504-8. PubMed ID: 25080291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Routine HIV Opt-Out Screening and Continuum of Care Services Following Entry into Eight Prison Reception Centers--California, 2012.
    Lucas KD; Eckert V; Behrends CN; Wheeler C; MacGowan RJ; Mohle-Boetani JC
    MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(7):178-81. PubMed ID: 26914322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV outcomes at a Canadian remand centre.
    Subramanian Y; Khan MN; Berger S; Foisy M; Singh A; Woods D; Pyne D; Ahmed R
    Int J Prison Health; 2016 Sep; 12(3):145-56. PubMed ID: 27548017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic profile changes by highly active antiretroviral therapy in human immunodeficiency virus-infected patients.
    Duro M; Rebelo I; Barreira S; Sarmento-Castro R; Medeiros R; Almeida C
    Int J STD AIDS; 2015 Oct; 26(11):796-802. PubMed ID: 25281540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.